Severe Combined Immunodeficiency (SCID) Diagnosis Market to grow with a CAGR of 9.20%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Severe Combined Immunodeficiency (SCID) Diagnosis Market.
According
to TechSci Research report, “Global Severe Combined Immunodeficiency (SCID)
Diagnosis Market Industry Size, Share, Trends, Competition, Opportunity and
Forecast, 2018-2028”, Global
Severe Combined Immunodeficiency (SCID) Diagnosis Market has valued at USD
182.60 million in 2022 and is anticipated to witness an impressive growth in
the forecast period with a CAGR of 9.20% through 2028. This can be due to collaborations and
partnerships among leading companies with a diverse approach to merge the
expertise of individual companies and to strengthen their position in the
market.
Newborn screening programs play a significant
role in driving the demand for the Global Severe Combined Immunodeficiency
(SCID) Diagnosis Market. Newborn screening programs are designed to detect SCID
in infants shortly after birth, often within the first few days of life. This
early detection is crucial because it allows for timely intervention and
treatment, reducing the risk of severe infections and complications associated
with SCID. In many regions, newborn screening for SCID is becoming a standard
practice and is included in universal newborn screening panels. This means that
all newborns are screened, regardless of their risk factors or family history
of SCID. Infants with SCID may appear healthy at birth and not show obvious
symptoms. Newborn screening identifies affected infants before they develop
symptoms, ensuring that they receive prompt medical attention. Newborn
screening programs for SCID have been associated with a significant reduction
in mortality rates among affected infants. Early diagnosis allows for timely
initiation of treatment, such as hematopoietic stem cell transplantation (HSCT)
or gene therapy, which can be lifesaving. Early intervention and treatment can
lead to better outcomes for children with SCID, improving their overall quality
of life. With appropriate care, many SCID patients can lead relatively normal
lives. Detecting SCID early through newborn screening can lead to cost savings
in the long run by preventing severe infections, hospitalizations, and the need
for more extensive and expensive medical interventions.
Severe
combined immunodeficiency (SCID) is a group of rare disorders caused by gene
mutations that affect the development and functioning of immune cells responsible
for fighting infections. Typically, the diagnosis of SCID involves a thorough
medical history and a physical examination of the affected child. To confirm
the diagnosis, additional blood tests, including a complete blood cell count,
may be conducted. X-linked severe combined immunodeficiency (X-linked SCID) is
a hereditary immune system disorder that overwhelmingly affects males. Due to a
deficiency in essential immune cells, boys with X-linked SCID are susceptible
to recurrent and prolonged infections caused by various bacteria, viruses, and
fungi.
In
September 2021, A review of newborn blood spot screening for severe combined
immunodeficiency (SCID) in England was started by Public Health England (PHE),
the UK National Screening Committee (UK NSC), NHS England, and NHS Improvement
(NHSEI). It will be evaluated to see if
SCID screening in England will be as effective as it has been in other nations
with varied demographics and healthcare systems. Rare immune system disorders
known as SCID make it particularly difficult for infants to fend against common
illnesses. Without therapy, SCID newborns typically pass away before they turn
a year old. Early diagnosis also
increases the likelihood that the SCID therapy (a bone marrow transplant) will
be effective and reduces the amount of time the infant must be sick or in the
hospital for testing. Infants who have a higher likelihood of having SCID will
be quickly sent to local immunology services for diagnostic tests.
Interpreting genetic variants is a significant
challenge in the Global Severe Combined Immunodeficiency (SCID) Diagnosis
Market. SCID is a genetically heterogeneous condition, meaning that there are
multiple genes associated with different subtypes of SCID. Interpreting genetic
variants becomes challenging because each subtype may have its own set of
pathogenic mutations. Some genetic variants associated with SCID may be
extremely rare or unique to specific families or populations. These rare
variants can be challenging to interpret because there may be limited data
available about their pathogenicity. Different genetic variants can lead to
variations in the clinical presentation and severity of SCID. Some variants may
result in milder forms of the condition, making it difficult to identify
affected individuals based solely on symptoms. Novel or previously unidentified
genetic variants continue to be discovered through genetic testing and
research. Interpreting the pathogenicity of these new variants requires careful
assessment and may involve functional studies to confirm their significance. In
genetic testing, variants that do not have a known or well-established
pathogenic role may be classified as "Variants of Uncertain
Significance" (VUS). Interpreting VUS is challenging because their
clinical significance is unclear, and they may or may not be related to SCID.
Browse
over XX market data Figures and spread through 110 Pages and an in-depth TOC
on "Global Severe Combined Immunodeficiency (SCID) Diagnosis Market.”
Global Severe Combined Immunodeficiency (SCID)
Diagnosis Market is segmented based on Disease Type, Test Type, End-User, and
by region.
Based on Test
Type Global Severe Combined Immunodeficiency (SCID) Diagnosis Market is
segmented into TREC, Complete blood count (CBC), Genetic Test, Biochemical
Test, and others. A Complete
Blood Count (CBC) is a common blood test that provides valuable information
about the composition and health of a person's blood. It is one of the most
frequently ordered blood tests and is used for various Red Blood Cell (RBC)
Count measures the number of red blood cells in each volume of blood. RBCs are
responsible for carrying oxygen from the lungs to the body's tissues and
returning carbon dioxide to the lungs for exhalation. An abnormal RBC count can
indicate conditions like anemia (low RBCs) or polycythemia (high RBCs). medical
purposes, including diagnosing and monitoring a wide range of medical
conditions. Hemoglobin is a protein in red blood cells that binds to oxygen and
gives blood its red color. The hemoglobin level reflects the blood's ability to
carry oxygen. Abnormal hemoglobin levels are associated with anemia or other
blood disorders. Hematocrit
measures the percentage of the blood volume occupied by red blood cells. It
provides information about blood viscosity and can indicate conditions such as
anemia or dehydration.
Based on Region, North America dominated the Global Severe Combined Immunodeficiency (SCID) Diagnosis
Market. Access to healthcare services, including diagnostic tests, is
facilitated by a relatively high rate of health insurance coverage in North
America. This ensures that patients have the means to undergo SCID testing.
North America has active patient advocacy groups and organizations dedicated to
rare diseases like SCID. These groups raise awareness, promote early testing,
and advocate for better access to diagnostics and treatments. The region is
home to many leading immunologists, geneticists, and pediatric specialists who
have expertise in diagnosing and treating SCID. Their knowledge and experience
contribute to accurate and timely diagnoses. In some cases, government support
and funding for research and rare disease programs have played a role in
advancing SCID diagnosis and treatment options. North American healthcare
professionals and researchers often collaborate with international experts and
organizations, contributing to the global understanding and management of SCID.
Asia-pacific region to witness fastest growth in the
Global Severe Combined
Immunodeficiency (SCID) Diagnosis Market. Many countries in the
Asia-Pacific region have been investing in the expansion and modernization of
their healthcare infrastructure. This includes improving medical facilities,
diagnostic laboratories, and access to specialized healthcare services. Awareness
about rare diseases like SCID is on the rise in the Asia-Pacific region due to
efforts by healthcare organizations, patient advocacy groups, and educational
campaigns. Increased awareness can lead to more infants being tested for SCID,
contributing to the growth of the diagnosis market. Some countries in
Asia-Pacific have initiated or expanded newborn screening programs to include
SCID. Newborn screening allows for early detection and intervention, driving
the demand for diagnostic tests. The Asia-Pacific region is home to a
significant portion of the global population. The sheer number of births in
this region contributes to a larger pool of potential SCID cases, which can
drive the demand for diagnostic testing.
Some
of the major companies operating in the Global
Severe Combined Immunodeficiency (SCID) Diagnosis Market include:
- ARCHIMED
SAS
- PerkinElmer
LAS Inc
- Health
Research, Inc
- Winfertility
Inc.
- Portea
Medical
- LaCAR
MDX Technologies
- Labsystems
Diagnostics Oy
- Devyser
Diagnostics
- Revcovi
- Leadiant
Biosciences Inc.
Download Free Sample Report
Customers can also request 10% free
customization on this report.
“Certain areas, particularly in North
America, are projected to exert significant demand for Severe Combined
Immunodeficiency (SCID) Diagnosis. The growth in the competitive landscape and
the presence of well-established companies in the market, committed to enhance
the overall wellbeing of people each year, are expected to contribute to a
remarkable growth of the Global Severe Combined Immunodeficiency (SCID)
Diagnosis Market in the forecast period," said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based Global management consulting
firm.
Severe Combined Immunodeficiency (SCID) Diagnosis Market – Global Industry Size, Share, Trends Segmented by Disease Type (X-linked SCID, ADA-SCID, others), By Test Type (TREC, Complete blood count (CBC), Genetic Test, Biochemical Test, others), By End User (Hospitals, Diagnostic and Research Laboratories, Others), by region, and Competition, Opportunity, and Forecast 2018-2028F" has evaluated
the future growth potential of Global Severe Combined Immunodeficiency (SCID)
Diagnosis Market and provides statistics & information on market size, structure,
and future market growth. The report intends to provide innovative market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Severe Combined
Immunodeficiency (SCID) Diagnosis Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com